|1.||Mudde, Geert C: 2 articles (06/2007 - 12/2006)|
|2.||Schuster, Manfred: 2 articles (06/2007 - 12/2006)|
|3.||Kircheis, Ralf: 2 articles (06/2007 - 12/2006)|
|4.||Halanek, N: 1 article (05/2009)|
|5.||Wiederkum, S: 1 article (05/2009)|
|6.||Szolar, O H J: 1 article (05/2009)|
|7.||Zinoecker, I: 1 article (05/2009)|
|8.||Nechansky, A: 1 article (05/2009)|
|9.||Kircheis, R: 1 article (05/2009)|
|10.||Siegl, P: 1 article (05/2009)|
12/01/2006 - "These data indicate that tumor cell growth inhibition by IGN311 cannot solely be accounted for by invoking cellular and humoral immunological mechanisms. "
12/01/2006 - "Treatment with IGN311 was associated with a down-regulation of ErbB1 in the excised tumor tissue. "
12/01/2006 - "IGN311 inhibited the growth of tumors derived from A431 cells xenografted in nude mice. "
06/01/2007 - "Here, the expression of the tumor antigen-specific antibody IGN311 was performed in a glyco-optimized strain of the moss Physcomitrella patens. "
06/01/2007 - "During the analytical characterization of the humanized Lewis-Y specific monoclonal antibody IGN311 (IgG1/kappa) used for passive anti-cancer therapy in humans, isoelectric focusing (IEF) experiments revealed that IGN311 batches produced in serum-containing and serum-free medium, respectively, displayed different banding patterns. "
|2.||Breast Neoplasms (Breast Cancer)
|2.||Growth Factor Receptors
|3.||Immunoglobulin G (IgG)
|4.||Complement System Proteins (Complement)